Wuxi Vision Pro is a technology company.
Wuxi Vision Pro has raised $18.0M across 2 funding rounds.
Wuxi Vision Pro has raised $18.0M in total across 2 funding rounds.
Wuxi Vision Pro has raised $18.0M in total across 2 funding rounds.
Wuxi Vision Pro's investors include Qiming Venture Partners.
Wuxi Vision Pro is a medical technology company founded in 2010 and headquartered in Wuxi City, China, specializing in the research, development, production, and marketing of ophthalmic materials and devices, particularly intraocular lenses (IOLs).[1][3][5] It manufactures products like the Leiming brand aspheric IOLs, which have obtained CFDA approval in China, CE certification in Europe, and FDA registration in the US, serving cataract patients and eye care professionals amid rising demand driven by aging populations and screen-related eye strain.[1][3][4][6] The company has raised $12.63 million in Series B funding from Qiming Venture Partners and Ruijian Capital, operates a lens materials facility in Irvine, California, and maintains ISO-13485 certification with a focus on high-quality, affordable ophthalmic solutions.[1][3][4]
Wuxi Vision Pro was established at the end of 2010 by Dr. Liao Xiugao in Wuxi City, Jiangsu Province, China, approximately 120 km from Shanghai.[1][3][4] Dr. Liao, recognizing the accelerating eye health challenges from modern lifestyles—such as excessive screen use hastening eye aging and diseases among younger people—founded the company to address the growing need for advanced ophthalmic products, particularly for China's estimated 130 million potential cataract patients over age 60.[1][4] Early milestones include building a state-of-the-art research and production facility, securing SFDA (now CFDA) registration, ISO-13485 certification, and achieving pivotal regulatory approvals like CFDA and CE for its Leiming aspheric IOLs, alongside FDA establishment registration.[3][4][6] A key traction point came in 2018 with $12.6 million in Series B financing, enabling global expansion, including its US manufacturing site in Irvine.[1][4]
Wuxi Vision Pro rides the global surge in ophthalmic medtech, fueled by aging demographics, a 20% annual growth in China's cataract surgeries, and lifestyle-driven eye diseases from digital overuse, with market forces like China's push toward 3,500+ surgeries per million by 2020 amplifying demand.[1][4] Its timing aligns with Asia's medtech boom, where local innovation reduces reliance on imports, and international facilities bridge Eastern manufacturing scale with Western R&D standards.[1][3] The company influences the ecosystem by supplying IOLs to global manufacturers, advancing affordable eye care in underserved regions, and contributing to trends like aspheric lens tech for better post-surgical vision.[4]
Wuxi Vision Pro is poised for expansion through new product pipelines, leveraging its 2018 funding for scaling production and entering more markets amid sustained cataract demand.[1][2][4] Trends like AI-enhanced diagnostics, premium IOL adoption, and China's medtech self-sufficiency will shape its path, potentially driving further funding or partnerships.[2] Its influence may grow as a key player in Asia-Pacific eye care, evolving from niche IOL maker to broader ophthalmic leader—echoing its founding mission to combat modern eye health crises with innovative, accessible devices.[1][4]
Wuxi Vision Pro has raised $18.0M across 2 funding rounds. Most recently, it raised $13.0M Series B in April 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2018 | $13.0M Series B | Qiming Venture Partners | |
| Sep 1, 2015 | $5.0M Series A | Qiming Venture Partners |